Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer

Summary

PG2 has been approved in Taiwan to treat cancer-related fatigue for advanced cancer patients. The primary objective of this study is to evaluate the efficacy of PG2 on fatigue relief in patients undergoing palliative abdominal surgery for cancer. The secondary endpoints, including the length of hospital stay, postoperative complications, HRQL, inflammatory biomarkers, the duration of antibiotic therapy, mortality during the hospital stay, weight loss and body composition, will be evaluated among these patients.

Timeline

Start

2014-02

Primary completion

2020-12

Completion

2020-12

Outcome

Outcome not reported

Stopped: “Study reevaluation”

Drugs

Indications